@article{1d9d1b37d4d347a1aef8517e8a3fc2b1,
title = "Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis",
abstract = "Background /Aims: Interleukin-10 (IL-10) has been ascribed pro-viral but anti-fibrotic properties in chronic hepatitis C virus (HCV) infection. In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection. Methods: Peripheral HCV-specific T-cell IL-10 and IFNγ responses were measured in cytokine Elispot assay using overlapping HCV-derived peptides in patients with chronic (n = 61), resolved (n = 15) and acute (n = 8) hepatitis C, looking for their onset, quantity, breadth and durability relative to clinical and virological outcomes. The source and effect of HCV-specific IL-10 response were determined in depletion and IL-10 neutralization experiments. Results: Both HCV-specific IL-10 and IFNγ responses were detected early within 1-2 months of acute clinical hepatitis C. However, only HCV-specific IL-10 response correlated with elevated liver enzymes, increased viremia and suppressed HCV-specific CD4+ T-cell proliferation in acute infection. While these associations were lost in established chronic infection, HCV-specific IL-10 responses were increased in patients without cirrhosis while IL-10 blockade enhanced antiviral effector IFNγ responses. Conclusions: HCV-specific IL-10 Tr1 responses may play a dual role in HCV infection, dampening effector T-cells to promote viral persistence in acute infection but also protecting against progressive fibrosis in chronic infection.",
keywords = "CD8 T-cells, HCV, Hepatitis C, IL-10, Interferon-gamma, Interleukin-10, Regulatory T-cells",
author = "Kaplan, {David E.} and Fusao Ikeda and Yun Li and Nobuhiro Nakamoto and Sutharsan Ganesan and Valiga, {Mary E.} and Nunes, {Frederick A.} and {Rajender Reddy}, K. and Chang, {Kyong Mi}",
note = "Funding Information: This material is based upon work supported in part by the Office of Research and Development, Department of Veterans Affairs and with the resources and the use of facilities at the Philadelphia VA Medical Center. This study was also supported by NIH Grants R01-AI-47519 and R01-AA-12849; the Philadelphia VA Medical Research; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306 and its Molecular Biology and Cell Culture Core Facilities; the NIH Public Health Service Research Grant M01-RR00040. D.E.K. was supported by the NIH T32 DK 07066, NIH Loan Repayment Program, AASLD/Schering Advanced Hepatology Fellowship, NIH K12-RR-017625, and the VA Career Development Award and the VA Stars and Stripes Award. The authors thank Dr Michael Houghton at Chiron Corporation for the generous provision of the recombinant HCV antigens and Colleen Brensinger, MS for statistical support. Funding Information: The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the materials involved either in the past or present and they did not receive funding from the manufacturers to carry out their research. NIH funded study (Grants R01-AI-47519, R01-AA-12849, P30DK50306, M01-RR00040, NIH T32 DK 07066, NIH K12-RR-017625). ",
year = "2008",
month = jun,
doi = "10.1016/j.jhep.2008.01.030",
language = "English",
volume = "48",
pages = "903--913",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",
}